Graf Acquisition Corp. IV (GFOR) Adjourns NKGen Completion Vote for Fourth Time
by Kristi Marvin on 2023-09-22 at 9:07am

Graf Acquisition Corp. IV (NYSE:GFOR) announced that it adjourned Wednesday’s completion vote for its combination with NKGen Biotech without conducting any business and will reopen proceedings at 4:00 p.m., Eastern time, on September 25, 2023

Once again, the adjournment is being done to provide additional time to continue its efforts to obtain additional financing. This new cash may be in the form of equity, debt, grants or other equity-linked securities. However, GFOR most recently added a $10M convertible note as well as a $2 million warrant subscription agreement (1,999,998 warrants at a cost of $1.00 per warrant) and at announcement, Graf IV’s combination included a backstop of up to $25 million funded by NKGen’s majority shareholder NKMax (KOSDAQ:182400).  Previously, this deal had a $50 million minimum cash condition, but according to today’s press release that has now been waived.

Furthermore, GFOR’s sponsors waived the requirement that certain NKGen Stockholders holding 5% or more of the shares of NKGen common stock on a fully-diluted basis as of the date of the Merger Agreement (other than NKMAX and certain NKGen directors and officers) enter into the Lockup Agreement. The effect of this waiver will be that an aggregate of approximately 2,377,171 of the shares of Common Stock held by such NKGen Stockholders after the Closing will be freely tradeable and not subject to lockup restrictions.

In light of these changes, Graf IV has filed a supplement to its proxy. The record date remains the same, which means that stockholder of record as of August 7, 2023 are entitled to vote at the meeting.

The $160 million combination was initially announced in April of this year. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.

Last month, NKGen announced that it had dosed the first patient with its candidate SNK-02 as a part of Phase I studies into the its efficacy in treating solid tumors.

 

Recent Posts
by Nicholas Alan Clayton on 2024-05-23 at 3:58pm

Churchill VII (NYSE:CVII) has upped its enterprise value of target CorpAcq by +10.1% to $1.74 billion from $1.58 billion, according to a refreshed investor presentation released this morning. The new deck also provides some new numbers on CorpAcq’s estimated 2023 results and sheds some light on why Churchill VII may have postponed its May 21...

by Nicholas Alan Clayton on 2024-05-23 at 11:59am

Centurion Acquisition Corp. (NASDAQ:ALFUU) has filed for a $250 million IPO with a commitment by its sponsor group to try and get to its full allotment in-house. The S-1 includes language that “The sponsor limited partners have expressed to us an interest in purchase up to an aggregate of approximately $283,500,000 of the units in this...

by Nicholas Alan Clayton on 2024-05-23 at 7:54am

At the SPAC of Dawn When British regulators adopted new SPAC rules in 2021, it was in part to try and lure more business back to UK exchanges while the SPAC boom was ongoing in the US. Instead, UK-based SPAC volume has remained low and the country’s latest SPAC deal will actually take its target...

by Nicholas Alan Clayton on 2024-05-22 at 1:59pm

Perceptive Capital Solutions (NASDAQ:PCSC) has filed for a $75 million IPO with an experienced team able to drive ambitious terms. It becomes just the second SPAC in six months to file for a vehicle without either warrants or rights and it would become one of a select few teams that have gotten such a vehicle...

by Nicholas Alan Clayton on 2024-05-22 at 7:42am

At the SPAC of Dawn Autonomous driving de-SPACs gained a new playground this week as the UK has passed expansive new legislation allowing for autonomous vehicle testing and use on British roads. The new law will clarify liability issues around collisions and beef up its regulatory arm that considers new vehicles to be approved for...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved